SectorBiological Technology
Established Date30/03/2022
Listing Date14/09/2021
ExchangeNASDAQ Stock Exchange
Full-time Employees3
Fiscal Year Ends31/12
Security TypeCommon stock
Office address5858 Horton Street, Suite 370, Emeryville, California 94608
Business
IntroductionEstrella Immunopharma, Inc., was incorporated in Delaware on March 30, 2022. The Company is a clinical-stage biopharmaceutical company utilizing its proprietary ARTEMIS technology to develop T-cell therapies for hematological cancers and solid tumors. Its main drug candidate EB103 targets CD19 for the treatment of B-cell malignancies, while a dual-targeted drug candidate EB104 is also being developed.
